The Woods Hole Film Festival will continue its 2021 series of virtual programming with the feature documentary âJim Allison: Breakthroughâ by Bill Haney, narrated by Woody Harrelson, Thursday, May 6 through Sunday, May 9. The festival will host a live online line question and answer session with the filmmakers on Saturday, May 8, at 7 PM.
The film will be available to watch between Thursday, May 6 at 8 AM and Sunday, May 9 at midnight. A free ticket to the virtual question and answer session will be made available at ticket purchase. Once home viewing is started, viewers will have 48 hours to finish watching, or until midnight on Sunday, May 9, whichever comes first.
Date Time
Australian drug discovery to be studied in US
A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.
The trial, which is being funded through a grant from the Charlie Teo Foundation, will enter pre‐clinical efficacy testing for glioblastoma (GBM). GBM is the most common form of brain cancer with an average survival of only 15 months from diagnosis.
The grant of $186,837 will go towards the study of PXS‐5505 at The University of Texas MD Anderson Cancer Center. The drug is a potent inhibitor of lysyl oxidase that is thought to play a crucial role in GBM because they attract inflammatory cells that accelerate tumour growth and reduce survival.
Date Time
Study explores how private equity acquisitions impact hospitals
Private equity investment in hospitals has grown substantially in the 21st century, and it accelerated in the years leading up the COVID-19 pandemic. Now a new study of short-term acute care hospitals acquired by private equity firms finds they not only have higher markups and profit margins, they’re also slower to expand their staffs.
In a study published in Health Affairs, a multi-institutional team of investigators led by Dr. Anaeze C. Offodile II, a nonresident scholar in the Center for Health and Biosciences at Rice University’s Baker Institute for Public Policy, the Gilbert Omenn Fellow at the National Academy of Medicine and an assistant professor of plastic and reconstructive surgery at The University of Texas MD Anderson Cancer Center, examined private involvement in short-term acute care hospitals and combed through proprietary databases to identify private equity transactions involving such ho
2021-05-03 by Proactive Australia
Pharmaxis Ltd (ASX:PXS)(FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer.
The drug, PXS-5505, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.
A$186,837 research grant
Charlie Teo Foundation has awarded a A$186,837 research grant to Y Alan Wang, PhD, associate professor of Cancer Biology at The University of Texas MD Anderson Cancer Center to enable the study of PXS-5505.
Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer
PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis. Charlie Teo Foundation founder and director Professor Charlie Teo and Pharmaxis CEO Gary Phillips during a TV interview.
Pharmaxis Ltd (ASX:PXS) (FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer.